The genetic basis of hereditary medullary thyroid cancer: Clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 871-884

  Sakorafas, George H ^a   Friess, Helmut ^b   Peros, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; CANCER GENETICS; CARCINOGENESIS; CERVICAL LYMPH NODE; DNA DETERMINATION; EARLY DIAGNOSIS; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; RECURRENT CANCER; REVIEW; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING;

CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHYSICIAN'S ROLE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 58249095068     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0098     Document Type: Review

References (129)

1. Ashworth M 2005 The pathology of preclinical medullary thyroid carcinoma. Endocrine Pathology 15 227-232.
2. Barbot N, Calmettes C, Schuffenecker I, Saint-Andre JP, Franc B, Rohmer V, Jallet P & Bigorgne JC 1994 Pentagastrin stimulation test and early diagnosis of MTC using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary MTC. Journal of Clinical Endocrinology and Metabolism 78 114-120.
3. Bergholm U, Adami HO, Bergstrom R, Backdahl, M & Akerstrom G 1990 Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference fo clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chirurgica Scandinavica 156 37-46.
4. Bergholm U, Bergstrom R & Ekbom A 1997 Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79 132-138.
5. Berndt I, Reuter M, Saller B, Frank-Rauer K, Groth P, Grussendorf M, Rauer F, Ritter MM & Hoppner W 1998 A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism 83 770-774.
6. Bigner SH, Cox EB, Mendelsohn G, Baylin SB, Wells SA Jr & Eggleston JC 1981 Medullary carcinoma of the thyroid in the multiple endocrine neoplasia IIA syndrome. American Journal of Surgical Pathology 5 459-472.
7. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Mourat A & Schlumberger M 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10 2415-2419.
8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG & Libroia A 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671.
9. Bugalho MJ, Domingues R, Santos JR, Catarino AL & Sobrinho L 2007 Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141 90-95.
10. Butter A, Gagne J, Al-Jazaeri A, Emran MA, Deal C & St-Vil D 2007 Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschprung's disease. Journal of Pediatric Surgery 42 203-206.
11. Calender A, Giraud S, Schuffenecker I, Lenoir GM, Gaudray P, Courseaux A, Porchet N, Aubert JP & Zhang CX 1997 Genetic testing in presympomatic diagnosis of multiple endocrine neoplasia. Hormone Research 47 199-210.
12. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ & Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. PNAS 91 1579-1583.
13. Carney JA, Go VL, Sizemore GW & Hayles AB 1976 Alimentary tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2 B. New England Journal of Medicine 295 1287-1291.
14. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J & Pharoah PD 2005 Polymorphisms in the initiators of RET signalling pathway and susceptibility to sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 90 6268-6274.
15. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M & Billaud M 1998 Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17 2851-2861.
16. Clayman GL & El-Baradie TS 2003 Medullary thyroid cancer. Otolaryngologic Clinics of North America 36 91-105.
17. Cohen R, Campos JM, Salaun C, Heshmati HM, Proye C, Sarfati E, Henry JF, Niccoli-Sire P & Modigliani E 2000 Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 85 919-922.
18. Colombo-Benkmann M, Raff J, Raue F, Klar E & Herfarth C 1998 Effect of primary surgical therapy on the course of C-cell carcinoma of the thyroid gland. Langenbeck's Archives of Surgery 115 1041-1043.
19. Colombo-Benkmann M, Bramswig J, Hoppner W, Gellner R, Hengst K, Bocker W & Senninger N 2002 Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia. World Journal of Surgery 26 1286-1290.
20. Danko ME & Skinner MA 2006 Surgical intervention in children with MEN type 2. Current Opinion in Pediatrics 18 312-315.
21. Decker RA 1992 Long-term follow-up of a large North American kindred with multiple endocrine neoplasia type 2A. Surgery 112 1066-1072.
22. Donis-Keller H, Don S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P & Wells SE Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 2 851-856.
23. Donovan DT, Levy ML, Furst EJ, Alford BR, Wheeler T, Tschen JA & Gagel RF 1989 Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hospital Medical Journal 37 147-150.
24. Dottorini ME, Assi A, Sironi M, Sangali G, Spreafico G & Colombo L 1996 Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathological variables. Cancer 77 1556-1565.
25. Dralle H, Scheumann GF, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berner M, Niederle B et al. 1995 The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentric study. Journal of Internal Medicine 238 357-361.
26. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R et al. 1998 Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World Journal of Surgery 22 744-750.
27. Ellenhom JD, Shah JP & Brennan MF 1993 Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 114 1078-1082.
28. Eng C 1999 RET in the development of human cancer. Journal of Clinical Oncology 17 380-393.
29. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Human Molecular Genetics 3 237-241.
30. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD & Ponder BA 1995a A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10 509-513.
31. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Newmann HP, Ponder MA & Ponder BA 1995b Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clinical Endocrinology 43 123-127.
32. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in MEN type 2. International RET mutation consortium analysis. Journal of the American Medical Association 276 1575-1579.
33. Evans DB, Fleming JB, Lee JE, Cote G & Gagel RF 1999 The surgical treatment of medullary thyroid carcinoma. Seminars in Surgical Oncology 16 50-63.
34. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS & Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. British Journal of Surgery 73 278-281.
35. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E & Colantuoni V 1998 A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Human Mutation 1 S167-S171.
36. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N & Jackson CE 2000 Variable expressivity of familial medullary thyroid carcinoma due to a RET V804M (GTG → ATG) mutation. Surgery 128 93-98.
37. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D & Schackert HK 2002 Various penetrance of famiial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Annals of Surgery 236 570-575.
38. Franck-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendt J et al. 1996 Mutations of the RET protooncogene in german MEN families: relation between genotype and phenotype. Journal of Clinical Endocrinology and Metabolism 81 1780-1783.
39. Friedell GH, Carey RJ & Rosen H 1961 Familial thyroid cancer. Cancer 15 241-245.
40. Frilling A, Weber F, Tecklenborg C & Broelsch CE 2003 Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbeck's Archives of Surgery 388 17-26.
41. Gagel RF, Tashjian AH Jr, Cumming T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ & Reichlin S outcome of prospective screening for MEN type 2A: a 18-year experience. New England Journal of Medicine 318 478-484.
42. Gertner ME & Kebebew E 2004 Multiple endocrine neoplasia type 2. Current Treatment Options in Oncology 5 315-325.
43. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS & Genel M 1996 Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA. Implications for therapy. Journal of Pediatrics 129 459-464.
44. Gimm O, Sutter T & Dralle H 2001 Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. Journal of Cancer Research and Clinical Oncology 127 156-165.
45. Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckboff M, Thanh PN, Frilling A, Klar E, Niederle B et al. 2002 RET proto-oncogene mutations affecting codon 790/791: a mild form of MEN type 2A syndrome? Surgery 132 952-959.
46. Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B & Dralle H 2004 Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A - related RET mutations not affecting codon 634. World Journal of Surgery 28 1312-1326.
47. Gosnell JE, Sywak MS, Sidhu SB, Gough IR, Learoyd DL, Robinson BG & Delbridge LW 2006 New era: prophylactic surgery for patients with MEN-2A. Australian and New Zealand Journal of Surgery 76 586-590.
48. Guyetant S, Rousselet MC, Durigon M, Chappard D, Frank B, Guerin O & Saint-Andre JP 1997 Sex related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. Journal of Clinical Endocrinology and Metabolism 82 42-47.
49. Guyetant S, Dupre F, Bigorgne JC, Franc B, Dutrieux-Berger N, Lecomte-Houcke M, Patey M, Caillou B, Viennet G, Guerin O et al. 1999 Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease. Human Pathology 30 957-963.
50. Hansford JR & Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. Journal of Medical Genetics 37 817-827.
51. Hazard JB, Hawk WH & Crile G 1959 Medullary (solid) carcinoma of the thyroid. A clinico-pathologic entity. Journal of Clinical Endocrinology 19 152-155.
52. Heizmann O, Haecker FM, Zumsteg U, Muller B, Oberholzer M & Oertli D 2006 Presymptomatic thyroidectomy in MEN type 2A. European Journal of Surgical Oncology 32 98-102.
53. Heshmati HM, Ghabih H, van Heerden JA & Sizemore GW 1997 Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. American Journal of Medicine 103 60-69.
54. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, van Amstel HK & Heineman E 1999 Predictive DANN testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. Journal of Pediatric Surgery 34 568-571.
55. Hofstra RMW, Landsvater RM, Ceccherini I, Stupl RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G et al. 1994 A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 375-376.
56. Hofstra. RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V & Buys CH 1997 A novel point mutation in the intracellular domain the ret proto-oncogene in a family with medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 82 4176-4178.
57. Howe JR, Norton JA & Wells SA Jr 1993 Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114 1070-1077.
58. Iler MA, King DR, Ginne-Pease ME, O'Dorisio TM & Sotos JF 1999 Multiple endocrine neoplasia type 2A: a 25-year review. Journal of Pediatric Surgery 34 92-97.
59. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G & Takahashi M 1997 Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, gamilial medullary thyroid carcinoma, and Hirschprung's disease phenotype. Cancer Research 57 2870-2872.
60. Kakudo K, Carney JA & Sizemore GW 1985 Medullary carcinoma of the thyroid. Biologic behavior of the sporadic and familial neoplasm. Cancer 55 2818-2821.
61. Kallinowski F, Buhr HJ, Meybier H, Eberhardt M & Herfarth C 1993 Medullary carcinoma of the thyroid - therapeutic strategy derived from fifteen years of experience. Surgery 114 491-496.
62. Kaufman FR, Roe TF & Isaacs H Jr 1982 Metastatic medullary thyroid carcinoma in young children with mucosan neuroma syndrome. Pediatrics 70 263-267.
63. Kebebew E, Tresler PA, Siperstein AE, Duh OY & Clark OH 1999 Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Thyroid 9 127-131.
64. Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J & Heitz PU 1995 Analysis of RET protooncogene point mutations distinguishes heritable from non-heritable medullary thyroid carcinomas. Cancer 76 479-489.
65. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE & Evans DB 2005 RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 531-544.
66. Lallier M, St-Vil D, Giroux M, Huot C, Gaboury L, Oligny L & Desjardins JC 1998 Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. Journal of Pediatric Surgery 33 846-848.
67. Leboulleux S, Baudin E, Travagli JP & Schlumberger M 2004 Medullary thyroid carcinoma. Clinical Endocrinology 61 299-310.
68. Lee NC & Norton JA 2000 Multiple endocrine neoplasia type 2 B - genetic basis and clinical expression. Surgical Oncology 9 111-118.
69. Lips CJM 1998 Clinical management of the MEN syndromes: results of a computerized opinion poll at the 6th International Workshop on Multiple Endocrine Neoplasia and von-Hippel-Lindau disease. Journal of Internal Medicine 243 589-594.
70. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ et al. 1994 Clinical screening as compared with DNA analysis in families with MEN type 2A. New England Journal of Medicine 331 828-835.
71. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Cailou B, Conte C, Dallapicolla B, Giuffrida D, Bidart JM et al. 2002 Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. Journal of Clinical Endocrinology and Metabolism 87 1674-1680.
72. Machens A, Gimm O, Hinz R, Hoppner W, Boehm BO & Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. Journal of Clinical Endocrinology 86 1104-1109.
73. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B et al. 2003a Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 349 1517-1525.
74. Machens A, Holzhausen HJ, Thanh PN & Dralle H 2003b Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134 425-431.
75. Machens A, Ukkat J, Brauckhoff M, Gimme O & Dralle H 2005 Advances in the management of hereditary medullary thyroid cancer. Journal of Internal Medicine 257 50-59.
76. Melvin KE, Miller HH & Tashijan AH Jr 1971 Early diagnosis of medullary carcinoma of the thyroid gland by means fo calcitonin assay. New England Journal of Medicine 285 1115-1120.
77. Menacho IP, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH et al. 2005 RET - familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Research 65 1729-1737.
78. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L et al. 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Clinical Endocrinology 48 265-273.
79. Moore SW, Appfelstaedt J & Zaahl MG 2007 Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN 2. Journal of Pediatric Surgery 42 326-332.
80. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460.
81. NCCN Oncology Practice Guidelines 2005 (V.1.2005), www.nccn.org/ physician_gls/_guidelines.html.
82. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E & Conte-Devolx B 1997 Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 82 338-341.
83. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, Bstandig B, Modigliani E, Morange S, Schlumberger M et al. 1999 Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. European Journal of Endocrinology 141 468-474.
84. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Charbier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S et al. 2001 Familial medullary thyroid carcinoma (FMTC) with non cysteine RET mutations: study in a large series of patients. Journal of Clinical Endocrinology and Metabolism 86 3746-3753.
85. Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF et al. 2003 When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 134 1029-1036.
86. Normann T 1977 Medullary thyroid carcinoma in Norway: epidemiology and genetic data. Acta Pathologica et Microbiologica Scandinavica 85 775-786.
87. Nunziata V, Giannattasio R, di Giovanni G, D'Armiento MR & Mancini M 1989 Herditary localized prutitus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome). Clinical Endocrinology 30 57-63.
88. Olson JA Jr, DeBenedetti MK, Baumann DS & Wells SA Jr 1996 Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Annals of Surgery 223 472-480.
89. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS & van Heerden JA 1995 Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118 936-942.
90. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, DiCoscio G, Miccoli P & Pinchera A 1994 Routine measurement of secum calcitonin in nodular thyroid disease allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 78 826-829.
91. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F, Iacconi P, Basolo F, Martino E & Pinchera A 1995 Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 118 1031-1035.
92. Papotti M, Botto Micca F, Favero A, Palestini N & Bussolati G 1993 Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular trabecular and solid patterns. American Journal of Surgical Pathology 17 291-301.
93. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM & Billaud M 1997 Oncogene activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15 393-402.
94. Phay JE, Moley JF & Lairmore TC 2000 Multiple endocrine neoplasias. Seminars in Surgical Oncology 18 324-332.
95. Piolat C, Dyon JF, Sturm N, Pinson S, Bost M, Jouk PS, Plantaz D & Chabre O 2006 Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clinical Endocrinology 65 118-124.
96. Ponder BA 1999 The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Research 59 (Suppl 7) 1736S-1741S.
97. Ponder BA & Smith D 1996 The MEN H syndromes and the role of the ret proto-oncogene. Advances in Cancer Research 70 179-222.
98. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P & Easton DF 1988 Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1 397-401.
99. Poston GJ 1993 Medullary carcinoma of the thyroid. In Surgical Endocrinology, pp 270-276. Eds J Lynn & SR Bloom. Oxford: Butterworth-Heinemann.
100. Rodriguez GJ, Balsalobre MD, Pomares F, Torregrosa NM, Carbonell P, Glower G, Sola J, Tebar J & Parrilla P 2002 Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. Journal of the American College of Surgeons 195 159-166.
101. Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL & Rudkin BB 1997 Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene 14 265-275.
102. Samaan NA, Draznin MB, Halpin RE, Bloss RS, Hawikins E & Lewis RA 1991 Multiple endocrine syndrome type IIb in early childhood. Cancer 68 1832-1834.
103. Sanso GE, Domene HM, Garcia R, Pusiol E, De M, Roque M, Ring A, Perinetti H, Elsner B & Lorcansky S 2005 Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in MEN type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 94 323-330.
104. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 381-383.
105. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M & Raue F 2001 Prognostic value of codon 918 (ATG-ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. International Journal of Cancer 95 62-66.
106. Schmimke RN & Hartmann WH 1965 Familial amyloid producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Annals of Internal Medicine 95 1027-1039.
107. Scopsi L, Sampietro G, Boracchi P, Del BO R, Gullo M, Placucci M & Pilotti S 1996 Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78 2173-2183.
108. Shaba AR, Cohen T, Ghossein R & Tuttle M 2006 Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope 116 1704-1707.
109. Shapiro SE, Cote GC, Lee JE, Gagel RF & Evans DB 2003 The role of genetics in the surgical management of familial endocrinopathy syndromes. Journal of the American College of Surgeons 197 818-831.
110. Sipple JF 1961 Association of pheochromocytoma with carcinoma of the thyroid gland. American Journal of Medicine 31 163-166.
111. Skinner MA 2003 Management of hereditary thyroid cancer in children. Surgical Oncology 12 101-104.
112. Skinner MA, DeBenedetti MK, Moley JF, Norton JA & Wells SA Jr 1996 Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. Journal of Pediatric Surgery 31 177-182.
113. Skinner MA, Moley JA, Diley WG, Owzar K, Debenedetti MK & Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine 353 1105-1113.
114. Smith VV, Eng C & Milla PJ 1999 Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 213: implications for treatment. Gut 45 143-146.
115. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA & Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Annals of Surgery 228 320-330.
116. Statement of the American Society of Clinical Oncology 1996 Genetic testing for cancer susceptibility, adopted on February 20, 1996. Journal of Clinical Oncology 14 1730-1736.
117. Steiner AL, Goodman AD & Powers SR 1969 Study of a kindred with pheochromocytoma, hyperparathyroidism and Cushing's disease; multiple endocrine neoplasia type 2. Medicine 47 371-379.
118. Stjernholm MR, Freudenbourg JC, Mooney HS, Kinney FJ & Deftos LJ 1980 Medullary carcinoma of the thyroid before age 2 years. Journal of Clinical Endocrinology and Metabolism 51 252-253.
119. Szinnai G, Meier C, Komminoth P & Zumsteg UW 2003 Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 111 E132-E139.
120. Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C & Henry JF 2005 Lymph node involvmenet in macroscopic medullary thyroid carcinoma. British Journal of Surgery 92 449-453.
121. Ukkat B, Lorenz K, Hinze R, Thomusch O & Dralle H 2001 Importance of early screening and prophylactic thyroid-ectomy in asympomatic non index germline carriers. World Journal of Surgery 25 713-717.
122. Vasen HF, Nieuwenhuijzen Kruseman AC, Berkel H, Beukers EK, Delprat CC, van Doorn RG, Geerdink RA, Haak HR, Hackeng WH, Koppeschaar HP et al. 1987 Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. A study of 15 kindreds in the Netherlands. American Journal of Medicine 83 847-852.
123. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M & Brochu P 1982 Hirschprung's disease in a family with multiple endocrine neoplasia type 2. Journal of Pediatric Gastroenterology and Nutrition 1 603-607.
124. Vestergaard P, Vestergaard EM, Brockstedt H & Christiansen P 2007 Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated? World Journal of Surgery 31 996-1001.
125. Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG & Farndon JR 1982 The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Annals of Surgery 195 595-599.
126. Wells SA Jr, Chi DD, Toshima K, Delmer LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG & Molley JF 1994 Predictive DNA testing and prophylactic thyroidectomy in patients at risk for MEN type 2A. Annals of Surgery 220 237-250.
127. Williams EO 1963 A review of 17 cases of carcinoma of the thyroid and pheochromocytoma. Journal of Clinical Pathology 18 288-292.
128. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE & Evans DB 2003 Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Archives of Surgery 138 409-416.
129. You YN, Lakhani V & Wells SA 2007 New directions in the treatment of thyroid cancer. Journal of the American College of Surgeons 205 S45-S48.